Source: MIL-OSI Submissions
Source: Cann Group Limited (ASX: CAN)
New Zealanders with difficulty sleeping wanted for clinical trial
The medicine is a capsule containing CBD (cannabidiol), which does not get you “high”
Research aims to make CBD medicines available without a prescription from pharmacies
Cann Group Limited (ASX: CAN), Australia’s first licensed medicinal cannabis cultivator, is inviting people with difficulty sleeping to participate in a ground-breaking clinical trial to see if low doses of CBD (cannabidiol) might be able to help.
The trial, which has been running in Australia, is expanding into New Zealand with three new study sites opening in Christchurch, Nelson (Tasman), and Rotorua. Participant recruitment is being coordinated by specialist clinical trials company Evrima.
Eligible participants will be given either CBD capsules or a placebo, which they will take for 30 days to see if their sleep improves.
If CBD is shown to improve people’s sleep, Cann Group intends to register the medicine as an over-the-counter medicine in Australia, making it available at pharmacies without needing a prescription. Cann Group will then consider registering the medicine in other countries, including New Zealand.
Multinational pharmaceutical company Haleon (previously GSK Consumer Healthcare) has signed an agreement with Cann Group, giving Haleon exclusive evaluation rights for the potential marketing, distribution, and sale of the product in Australia, with the potential for rights in other countries as well.
Cann Group is manufacturing CBD capsules at its state-of-the-art medicinal cannabis cultivation and production facility in regional Victoria, Australia. With more than 34,000 sq. m of glasshouse and 12,000 sq. m of processing and support space, it is one of the largest medicinal cannabis facilities in the country.
Those interested in the trial can go to Evrima’s website www.cbdsleepstudy.com.au to register their interest and learn more about the study.
Cann Group CEO Peter Crock said, “Around 40% of adults have some kind of sleep disturbance, and we are interested to see if CBD can help with that. There is lots of optimism about medicinal cannabis, but so far very few placebo-controlled clinical trials have been conducted. Trials like Cann Group’s are necessary to properly assess the efficacy of medicinal cannabis for particular conditions, and to gain greater acceptance of these products by doctors, patients and the wider community.”
The study sites are:
Southern Clinical Trials Christchurch
Southern Clinical Trials Tasman
Lakeland Clinical Trials Rotorua
About Cann Group
Cann Group Limited (ABN 25 603 949 739) is building a world-class business focused on breeding, cultivating, manufacturing and supplying medicinal cannabis for sale and use within Australia and for approved export markets. Cann has established research, cultivation and GMP manufacturing facilities in Melbourne and a state-of-the-art large-scale cultivation and manufacturing facility near Mildura, Victoria. Cann Group’s leading position in plant genetics, breeding, extraction, analysis and production techniques supports its objective to supply high quality, safe medicinal cannabis for a range of diseases and medical conditions. Cann’s product portfolio incorporates its proprietary Satipharm delivery system for cannabinoids.
Learn more at: www.canngrouplimited.com | www.satipharm.com
